-
phaware, Antidote Technologies Recruiting Patients for Trials
Antidote Technologies, a digital health company, and phaware global association, an organization advocating for pulmonary hypertension (PH) awareness, will join forces to create a new recruitment system for pharmaceutical companies and contract research organizations (CROs) to enroll patients with chronic lung diseases in their clinical trials.
The partnership will bring together phaware’s proven patient engagement model and Antidote’s expertise on recruitment for clinical trials, to improve the recruitment efficiency of patients with PH and related diseases. Click here to read more about this story.
What are your thoughts on this news?
-
0 Replies
Sorry, there were no replies found.
Log in to reply.